A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Major Inclusion Criteria:

• Provision of written informed consent prior to any study-specific procedure
• Fasting LDL-C between 130 and 220 mg/dL following wash-out of all lipid regulating medications and supplements
• Fasting triglyceride <400 mg/dL following wash-out of all lipid regulating medications and supplements
• BMI between 18 and 35 mg/kg2

Major Exclusion Criteria:

• Clinically significant cardiovascular disease, diabetes or uncontrolled hypertension
• Females of child bearing potential (i.e., females who are not surgically sterile or post-menopausal)